Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 12/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.40 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6433182 | 0.87 | CTSK (0.58) | CTSKCTSSCTSLCTSB | |
| SCHEMBL4678780 | 0.73 | CTSK (0.66) | CTSKCTSSCTSLCTSB | |
| SCHEMBL18019199 | 0.72 | CTSS (0.49) | CTSKCTSSANPEPMAP1LC3BMAP1LC3A | |
| SCHEMBL20048685 | 0.71 | CTSK (0.48) | CTSKCTSSANPEPMAP1LC3BMAP1LC3A | |
| SCHEMBL5551615 | 0.70 | CTSK (0.56) | CTSKCTSSMAP1LC3BMAP1LC3AREN | |
| SCHEMBL25283632 | 0.69 | CTSK (0.76) | CTSKCTSSRENCTSLCTSB | |
| SCHEMBL4214306 | 0.69 | CTSK (0.76) | CTSKCTSSRENCTSLCTSB | |
| SCHEMBL6359855 | 0.69 | DYRK1A (0.51) | HPGDS | |
| SCHEMBL4224865 | 0.69 | CTSK (0.50) | CTSKCTSSCTSLCTSB | |
| SCHEMBL5556459 | 0.69 | CTSK (0.50) | CTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154048-A1 | Novel acyl hydrazino thiophene derivatives, process for preparing them, their use as medicinal products, pharmaceutical compositions and novel use | AVENTIS PHARMA S.A. (FR) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154048-A1 | Novel acyl hydrazino thiophene derivatives, process for preparing them, their use as medicinal products, pharmaceutical compositions and novel use | CTSZ, CTSE, CTSS | HPGDS 301/4885CTSK 8/4885CTSS 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.